NCT04893759 - A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 6, 2022

Primary Completion Date

September 14, 2022

Study Completion Date

September 14, 2022

Conditions

Neuroendocrine Tumors

Interventions

DRUG

Pelcitoclax

Multiple dose cohorts, 30 minute IV infusion, once a week, 28 days as a cycle

Trial Locations (3)

Fudan University Shanghai Cancer Center, Shanghai

The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou

Sun Yat-sen University Cancer Center, Guangzhou